OrthoPediatrics (KIDS) Panoramica del titolo
OrthoPediatrics Corp. è un'azienda di dispositivi medici che si occupa della progettazione, dello sviluppo e della commercializzazione di impianti, strumenti e tutori specializzati per bambini affetti da patologie ortopediche negli Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
KIDS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di OrthoPediatrics Corp.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$20.33 |
| Massimo di 52 settimane | US$23.70 |
| Minimo di 52 settimane | US$14.42 |
| Beta | 0.99 |
| Variazione di 1 mese | 10.13% |
| Variazione a 3 mesi | 27.30% |
| Variazione di 1 anno | -7.13% |
| Variazione a 3 anni | -54.21% |
| Variazione a 5 anni | -65.21% |
| Variazione dall'IPO | 5.78% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 24
KIDS: Pediatric Orthopedic Execution And 2026 Guidance Will Drive Upside Potential
OrthoPediatrics’ analyst price target has shifted modestly, with a recent $1 upward move and $3 downward moves leaving the Street view recalibrated as analysts weigh updated assumptions on discount rates, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on OrthoPediatrics reflects a mix of optimism and caution as analysts reassess their models, which has led to both upward and downward adjustments to the stock’s price target.Aggiornamento della narrazione • Jun 08
KIDS: 2026 Guidance Delivery Will Shape Upside From Pediatric Orthopedic Focus
Analysts have made a modest net reduction of $2 in their price targets for OrthoPediatrics, reflecting updated views on the stock that incorporate both more cautious and more optimistic research opinions. Analyst Commentary Recent research on OrthoPediatrics shows a mixed but measured stance, with one firm trimming its price target and another lifting theirs.Aggiornamento della narrazione • May 24
KIDS: 2026 Product Launches And Guidance Execution Will Drive Upside Potential
Narrative Update on OrthoPediatrics The updated analyst price target for OrthoPediatrics edges up from about $24.00 to roughly $24.67, as analysts factor in recent price target revisions across the Street and modest adjustments to long term growth, profitability, and future P/E assumptions. Analyst Commentary Recent Street commentary around OrthoPediatrics reflects a mix of optimism about the company’s long term opportunity and caution around execution and valuation, which together shape the modestly higher blended price target.
Aggiornamento della narrazione • May 07
KIDS: Cash Flow And 2026 Launches Will Offset More Cautious Long Range Assumptions
The analyst price target for OrthoPediatrics has been revised from $20 to $17 as analysts factor in slightly lower long range assumptions for revenue growth, profit margins, and future P/E, while still highlighting prior commentary around solid EBITDA, free cash flow, and contributions from upcoming product launches. Analyst Commentary Recent research shows a mix of views on OrthoPediatrics, with some analysts trimming expectations even as others highlight prior strength in EBITDA, free cash flow, and potential contributions from future product launches.Recent updates
Aggiornamento della narrazione • Jun 24
KIDS: Pediatric Orthopedic Execution And 2026 Guidance Will Drive Upside Potential
OrthoPediatrics’ analyst price target has shifted modestly, with a recent $1 upward move and $3 downward moves leaving the Street view recalibrated as analysts weigh updated assumptions on discount rates, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on OrthoPediatrics reflects a mix of optimism and caution as analysts reassess their models, which has led to both upward and downward adjustments to the stock’s price target.Aggiornamento della narrazione • Jun 08
KIDS: 2026 Guidance Delivery Will Shape Upside From Pediatric Orthopedic Focus
Analysts have made a modest net reduction of $2 in their price targets for OrthoPediatrics, reflecting updated views on the stock that incorporate both more cautious and more optimistic research opinions. Analyst Commentary Recent research on OrthoPediatrics shows a mixed but measured stance, with one firm trimming its price target and another lifting theirs.Aggiornamento della narrazione • May 24
KIDS: 2026 Product Launches And Guidance Execution Will Drive Upside Potential
Narrative Update on OrthoPediatrics The updated analyst price target for OrthoPediatrics edges up from about $24.00 to roughly $24.67, as analysts factor in recent price target revisions across the Street and modest adjustments to long term growth, profitability, and future P/E assumptions. Analyst Commentary Recent Street commentary around OrthoPediatrics reflects a mix of optimism about the company’s long term opportunity and caution around execution and valuation, which together shape the modestly higher blended price target.Aggiornamento della narrazione • May 07
KIDS: Cash Flow And 2026 Launches Will Offset More Cautious Long Range Assumptions
The analyst price target for OrthoPediatrics has been revised from $20 to $17 as analysts factor in slightly lower long range assumptions for revenue growth, profit margins, and future P/E, while still highlighting prior commentary around solid EBITDA, free cash flow, and contributions from upcoming product launches. Analyst Commentary Recent research shows a mix of views on OrthoPediatrics, with some analysts trimming expectations even as others highlight prior strength in EBITDA, free cash flow, and potential contributions from future product launches.
Aggiornamento della narrazione • Apr 22
KIDS: Solid Cash Generation And 2026 Launches Will Support Higher Upside
Narrative Update on OrthoPediatrics The Street price targets for OrthoPediatrics have nudged higher, with moves such as Truist's shift to $20 from $19 and Stifel's to $22 from $20, as analysts point to solid Q4 EBITDA, better free cash flow, and expected contributions from new product launches, along with confidence in the company's long-range revenue outlook of 12%. Analyst Commentary Recent research updates highlight a cluster of positive shifts in sentiment around OrthoPediatrics, centered on solid Q4 execution and growing confidence in the company’s long term revenue framework.Aggiornamento della narrazione • Apr 07
KIDS: Solid Cash Flow And 2026 Launches Will Support Long Range Outlook
Analyst price targets for OrthoPediatrics have ticked higher, with recent moves such as Truist lifting its target to $20 and Stifel to $22. These changes reflect analyst views that solid Q4 EBITDA, free cash flow and potential contributions from future product launches support the company’s long range revenue outlook.Aggiornamento della narrazione • Mar 24
KIDS: Solid Cash Generation And 2026 Launches Are Expected To Drive Upside
Analyst price targets for OrthoPediatrics have moved higher by $1 to a range of $20 to $22. This reflects analyst views that solid recent EBITDA and free cash flow, along with expected contributions from new products in 2026, support the company's long range 12% revenue outlook and a slightly higher fair value estimate.Aggiornamento della narrazione • Mar 09
KIDS: Solid Cash Flow And 2026 Launches Will Shape Balanced Outlook
Narrative Update: OrthoPediatrics The analyst price target for OrthoPediatrics has moved from $19 to $20. This change reflects analysts' views that recent solid Q4 EBITDA and free cash flow, along with expectations for contributions from planned product launches and long-range revenue growth, support a modestly higher fair value and a slightly higher future P/E assumption.Aggiornamento della narrazione • Feb 22
KIDS: Execution On 2026 Revenue Guidance Will Support Upside Potential
Analysts have trimmed their price target on OrthoPediatrics slightly to $24.00 from $24.13, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that remain broadly supportive of the positive view reflected in recent Street research. Analyst Commentary Recent Street commentary frames OrthoPediatrics as a higher risk, higher reward idea, where execution on growth plans and disciplined cost control are key to justifying the updated US$24.00 price target.Aggiornamento della narrazione • Feb 08
KIDS: Higher Margin Outlook Will Support Bullish Long Term Opportunity
Analysts have trimmed their price target on OrthoPediatrics by $3 to $19, citing updated assumptions for slightly slower revenue growth, a modestly higher discount rate, and a lower future P/E multiple, even though projected profit margins are set at a higher level. Analyst Commentary Even with higher projected profit margins in current models, some bearish analysts remain cautious on OrthoPediatrics.Aggiornamento della narrazione • Jan 25
KIDS: Revenue Visibility And Margin Progress Are Expected To Drive Long Term Upside
Analysts have lowered their price target on OrthoPediatrics, with one firm cutting its target to $26 from $42 as they factor in updated expectations for revenue growth and profitability, even as the company guides to revenue growth of over 12% over the next few years. Analyst Commentary Bullish analysts see the recent price target reset as more of a recalibration than a complete shift in sentiment.Aggiornamento della narrazione • Jan 11
KIDS: Reset Execution Expectations Should Support Upside From Revised Growth Outlook
Analysts have nudged their price target on OrthoPediatrics lower to about US$24.13 per share from roughly US$24.14, citing slightly reduced revenue growth and profit margin assumptions following recent quarterly results and updated company guidance around revenue growth of over 12% in the coming years. Analyst Commentary Analysts are parsing the latest update on OrthoPediatrics with a mix of optimism around growth and caution around execution and profitability.Aggiornamento della narrazione • Dec 24
KIDS: Core High Margin Segments Are Expected To Drive Long Term Upside
Analysts have reduced their price target on OrthoPediatrics from about $42 to roughly $33, citing lower long term revenue growth assumptions and a modestly higher discount rate, despite resilient margins and confidence in the company’s core high margin segments. Analyst Commentary Bullish analysts acknowledge that the recent price target reductions reflect tempered expectations for near term growth, but they continue to frame OrthoPediatrics as a long term execution story with attractive end market exposure.Aggiornamento della narrazione • Dec 10
KIDS: Reset Expectations Will Support Upside From Core High-Margin Franchise
Analysts trimmed their OrthoPediatrics price targets by roughly $6 to $10 per share across the Street, citing lowered revenue growth forecasts, below consensus Q3 results, and more conservative long term guidance, even as they maintained confidence in the company’s core, higher margin businesses. Analyst Commentary Street research following OrthoPediatrics' preliminary Q3 update reflects a mix of near term caution and longer term optimism, with price targets reset lower but most ratings remaining positive.Aggiornamento della narrazione • Nov 26
KIDS: Revenue Miss Expected To Set Up Double-Digit Upside Over The Next Year
Analysts have lowered their price targets for OrthoPediatrics by a wide margin, with several firm targets now in the $18 to $34 range. They cite recent revenue shortfalls and a more cautious growth outlook, despite continued confidence in the company's long-term fundamentals.Articolo di analisi • Nov 25
OrthoPediatrics (NASDAQ:KIDS) Is Making Moderate Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aggiornamento della narrazione • Nov 08
KIDS: Recent Revenue Shortfall Will Set Up Potential Longer-Term Surprise
OrthoPediatrics’ analyst price target has been reduced from approximately $26.29 to $24.14, as analysts cite more conservative revenue growth forecasts and recent performance shortfalls. This adjustment comes despite ongoing long-term confidence in the company’s fundamentals.Aggiornamento della narrazione • Oct 25
Expanding Global Reach Will Support Long-Term Outlook Amid Revenue Headwinds
Analysts have lowered their price targets for OrthoPediatrics, with targets dropping by $3 to $12 per share. They cite recent revenue shortfalls and reduced guidance, though many continue to highlight strength in the company’s core business fundamentals and long-term outlook.Aggiornamento della narrazione • Oct 11
International Clinic Openings And Product Launches Will Expand Global Reach
OrthoPediatrics’ consensus analyst price target has dropped sharply from approximately $33.86 to $26.29 per share. Analysts cite weaker-than-expected revenues due to challenges in select markets and product categories, although the company continues to demonstrate strength in core business fundamentals.Articolo di analisi • Sep 26
Investors Holding Back On OrthoPediatrics Corp. (NASDAQ:KIDS)
You may think that with a price-to-sales (or "P/S") ratio of 2x OrthoPediatrics Corp. ( NASDAQ:KIDS ) is a stock worth...Aggiornamento della narrazione • Aug 08
International Clinic Openings And Product Launches Will Expand Global Reach
OrthoPediatrics' valuation outlook is stable, with both the future P/E and net profit margin essentially unchanged, resulting in the consensus analyst price target holding steady at $33.86. What's in the News Expanded the OrthoPediatrics Specialty Bracing division with new clinics in California, Ohio, Colorado, New York, and internationally into Ireland, enhancing presence in key hospitals and entering new markets.Articolo di analisi • Apr 08
Is OrthoPediatrics (NASDAQ:KIDS) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Nuova narrazione • Mar 26
Pediatric Orthopedic Bracing Expansion Will Secure Market Leadership
Strategic focus on pediatric specialty bracing and product expansion aims for market dominance, improving EBITDA and future earnings growth.Articolo di analisi • Mar 06
OrthoPediatrics Corp.'s (NASDAQ:KIDS) Shares Not Telling The Full Story
There wouldn't be many who think OrthoPediatrics Corp.'s ( NASDAQ:KIDS ) price-to-sales (or "P/S") ratio of 3x is worth...Articolo di analisi • Nov 05
Investors Still Waiting For A Pull Back In OrthoPediatrics Corp. (NASDAQ:KIDS)
You may think that with a price-to-sales (or "P/S") ratio of 4x OrthoPediatrics Corp. ( NASDAQ:KIDS ) is a stock to...Articolo di analisi • Aug 09
The OrthoPediatrics Corp. (NASDAQ:KIDS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders might have noticed that OrthoPediatrics Corp. ( NASDAQ:KIDS ) filed its quarterly result this time last...Articolo di analisi • Aug 02
Shareholders Should Be Pleased With OrthoPediatrics Corp.'s (NASDAQ:KIDS) Price
OrthoPediatrics Corp.'s ( NASDAQ:KIDS ) price-to-sales (or "P/S") ratio of 4.5x may not look like an appealing...Articolo di analisi • May 09
OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets
As you might know, OrthoPediatrics Corp. ( NASDAQ:KIDS ) just kicked off its latest quarterly results with some very...Articolo di analisi • May 07
OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Articolo di analisi • Apr 10
Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S
With a price-to-sales (or "P/S") ratio of 4.9x OrthoPediatrics Corp. ( NASDAQ:KIDS ) may be sending bearish signals at...Articolo di analisi • Dec 20
Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S
OrthoPediatrics Corp.'s ( NASDAQ:KIDS ) price-to-sales (or "P/S") ratio of 5.5x may look like a poor investment...Articolo di analisi • May 05
Getting In Cheap On OrthoPediatrics Corp. (NASDAQ:KIDS) Might Be Difficult
You may think that with a price-to-sales (or "P/S") ratio of 8.4x OrthoPediatrics Corp. ( NASDAQ:KIDS ) is a stock to...Rendimenti per gli azionisti
| KIDS | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | 1.9% | -1.3% | 0.7% |
| 1Y | -7.1% | -18.6% | 20.6% |
Ritorno vs Industria: KIDS ha superato il US Medical Equipment che ha restituito -18.6 % nell'ultimo anno.
Rendimento vs Mercato: KIDS ha avuto una performance inferiore al mercato US che ha registrato un rendimento 20.6 % nell'ultimo anno.
Volatilità dei prezzi
| KIDS volatility | |
|---|---|
| KIDS Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: KIDS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di KIDS è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2006 | 602 | David Bailey | www.orthopediatrics.com |
OrthoPediatrics Corp. è un'azienda di dispositivi medici che si occupa di progettare, sviluppare e commercializzare impianti, strumenti e tutori specializzati anatomicamente appropriati per i bambini affetti da patologie ortopediche negli Stati Uniti e a livello internazionale. L'azienda offre prodotti per la correzione di traumi e deformità pediatriche, procedure per la scoliosi per il trattamento delle deformità spinali nei bambini, nonché prodotti per la medicina dello sport e altri prodotti. I suoi prodotti comprendono PediLoc, PediPlates, viti cannulate, chiodo PediFlex, PediNail, PediLoc Tibia, sistema di ricostruzione ACL, lama cannulata bloccante, femore prossimale bloccante, tavole Spica, colonna vertebrale RESPONSE, BandLoc, piattaforma di chiodatura pediatrica | femore, Devise Rail, Orthex, Sistema intramidollare telescopico Fassier-Duval, Chiodo SLIM, Chiodo GAP, Sistema di viti SCFE a scorrimento libero, Sistema di modulazione della crescita GIRO, Sistema PNP per tibia, Sistema ApiFix Mid-C, Mitchell Ponseti, VerteGlideTM e Boston Brace 3D.
OrthoPediatrics Corp. Riepilogo dei fondamenti
| KIDS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$519.61m |
| Utili (TTM) | -US$39.68m |
| Ricavi(TTM) | US$243.30m |
2.1x
Rapporto P/S-13.2x
Rapporto P/EKIDS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| KIDS Conto economico (TTM) | |
|---|---|
| Ricavi | US$243.30m |
| Costo del fatturato | US$65.51m |
| Profitto lordo | US$177.79m |
| Altre spese | US$217.47m |
| Utili | -US$39.68m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -1.54 |
| Margine lordo | 73.07% |
| Margine di profitto netto | -16.31% |
| Rapporto debito/patrimonio netto | 30.3% |
Come si è comportato KIDS nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/10 10:18 |
| Prezzo dell'azione a fine giornata | 2026/07/10 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
OrthoPediatrics Corp. è coperta da 11 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |